Relationships Between Thyroid Hormones, Insulin-Like Growth Factor-1 and Antioxidant Levels in Hypothalamic Amenorrhea and Impact on Bone Metabolism

Authors
Antonio Mancini1,2, Edoardo Vergani1,2, Carmine Bruno1,2, Angelina Barini3,4, Andrea Silvestrini3,4, Elisabetta Meucci3,4, Calogero Messana5,6, Daniela Romualdi3,4, Rosanna Apa5,6, Antonio Lanzone5,6

Affiliations
1 UOC Endocrinologia e Diabetologia, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy
2 Istituto di Patologia Speciale Medica e Semeiotica Medica, Università Cattolica del Sacro Cuore, Rome, Italy
3 Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy
4 Istituto di Biochimica e Biochimica Clinica, Università Cattolica del Sacro Cuore, Rome, Italy
5 UOC Ostetricia e Patologia Ostetrica, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy
6 Istituto di Clinica Ostetrico e Ginecologica, Università Cattolica del Sacro Cuore, Rome, Italy

Key words
amenorrhea, osteoporosis, non-thyroidal illness, osteocalcin, antioxidants

received 15.11.2018
accepted 11.02.2019

Bibliography
DOI https://doi.org/10.1055/a-0859-4285
Published online: 7.3.2019
Horm Metab Res 2019; 51: 302–308
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0018-5043

Correspondence
Prof. Antonio Mancini
Division of Endocrinology,
Catholic University of the Sacred Heart,
Largo A. Gemelli 8, 00168 Rome, Italy
Tel.: + 39/06/3015 4440, Fax: + 39/06/3015 7232
antonio.mancini@unicatt.it

Introduction
Secondary amenorrhea, defined as a 3 months absence of menstruation in a previously cycling woman, occurs in 3–5 % of women, and 20–35 % of them are affected by functional hypothalamic amenorrhea (FHA) [1]. FHA is a form of chronic anovulation, which is not related to an identifiable organic cause [2], classified as a hypogonadotropic hypogonadism [3]. It is a “functional” condition because the correction of causal behavioral factors, such as stress, anxiety, excessive physical exercise and weight loss, can normalize ovulatory function.

It is known that the main feature is a reduction in GnRH (gonadotropin-releasing hormone) signal, which manifests as reduced
lutenizing hormone (LH) pulse frequency [3] and follicle-stimulating hormone (FSH) levels insufficient to maintain an adequate folliculogenesis and ovulatory function as demonstrated by GnRH or gonadotropin exogenous use, which can guarantee folliculogenesis [3]. The consequent hypoestrogenism has a negative mark on different aspects of female health [4,5].

However, other endocrine and metabolic dysfunction, such as an activation in hypothalamic-pituitary-adrenal axis (HPA) [4,6], assayable serum growth hormone (GH) levels during night-time and lower 24 h prolactin (PRL) levels [7], low serum insulin and insulin-like growth factor 1 (IGF-1), have been described. Moreover, a consequence of the activation of HPA axis is the enhanced production of endogenous opioid peptides (mostly endorphins, enkephalins, and dynorphin) [8] and other neurohormonal factors involved in stress response such as dopamine, neotensin, serotonin [9] and several neuropeptides: substance P, neuropeptide Y (NPY), and calcitonin gene-related peptide (CGRP) [4].

An alteration of hypothalamic-pituitary-thyroid axis (HPT) has also been detected including a low-to-normal level of thyrotropin, a low level of triiodothyronine, and increased level of reverse triiodothyronine [5], a condition defined “non-thyroidal illness syndrome” (NTIS). Usually, this condition, described in other chronic disease, is considered an adaptive mechanism and its treatment is still debated. However, it could contribute to the clinical presentation of FHA.

One of the most frequent event is the decrease of bone mass density, related to an increase of fracture risk; it is possible to affirm that osteopenia and osteoporosis are the main long-term complications of FHA [5]. This problem has a great social relevance when considering the cost of morbidity and mortality, which usually are considered only in ageing population [10]. The prevalence in young population, before peak bone density is reached, strengthens the interest of the topic.

It is well known that improper diet, leading to low calcium and vitamin D3 intake, malnutrition, excessive exercises [11] and especially estrogens play a critical role in bone metabolism [12]. The result of estrogens activity is the activation bone remodeling units, an enhancement in bone formation and a suppression of bone resorption [12]. Androgens, FT3, GH, and IGF-1 are the other hormones, which exert a positive influence on bone formation [13], even if their role is not so clear as estrogens one.

One of the possible mechanism through which these hormones can exert their activity on bone may probably be oxidative stress (OS). OS is caused by the unbalancing between production of free radicals, molecules characterized by high reactivity due to one or more unpaired electrons in the external orbital, and antioxidant defenses in the biological systems [14]. Radical oxygen species (ROS) greatly influence the generation and survival of osteoclasts, osteoblasts, and osteocytes and loss of estrogens and androgens decrease defense against OS in bone [15]. On the other hand, different hormones are able to modulate antioxidant systems, as previously reviewed, in particular thyroid hormones [16] and NTIS have been related to OS.

The aim of this observational cohort study is therefore to evaluate the impact of hormonal alterations and antioxidant systems on bone turnover in FHA, with a particular focus on NTIS. In order to evaluate the impact of low FT3 on bone turnover parameters and antioxidant levels, we have divided the patients according to FT3 levels in 2 groups to explore the differences between low- and normal-FT3 patients, hypothesizing oxidative stress as a possible mechanism contributing to reduced bone mineral density (BMD) in such patients.

### Patients and Methods

Subjects involved in this study were admitted to the University Hospital “Policlinico Gemelli” Department of Internal Medicine and were enrolled after being given an explanation of purposes and nature of the study, conducted in accordance with the Declaration of Helsinki, as revised in 2013. The study protocol was approved by Review Board of the “Institute of Medical Pathology” of our Hospital and written informed consent was obtained from all patients.

We included 43 patients with diagnosis of hypothalamic amenorrhea lasting at least 3 months, confirmed by typical endocrine picture (see below) and absent response to medroxyprogesterone administration, according to the Endocrine Society Practice Guidelines [2]. They were aged 15–34 years, with a BMI range 17.3–23.4 kg/m².

Criteria of exclusion were: Anorexia nervosa according to DSM V criteria [17], diabetes mellitus, liver or kidney chronic failure, cortico-steroid therapy, hyperparathyroidism, obesity, malabsorption or other gastro-enteric diseases, and neurological diseases. Women with secondary amenorrhea due to other causes, specifically hyperprolactinemia, Cushing’s syndrome, congenital adrenal hyperplasia, polycystic ovarian syndrome or primary ovarian failure, were excluded.

Patients were divided in 2 groups according to FT3 levels: group A (low FT3, n = 22, FT3 values < 2.4 pg/ml according to laboratory range), group B (normal FT3, n = 21, FT3 values ≥ 2.4 pg/ml).

An endocrine evaluation including FT3, FT4, thyroid-stimulating hormone (TSH), IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), dehydroepiandrosterone-sulfate (DHEAS), testosterone (T), and cortisol levels was performed; bone metabolic parameters were also evaluated (25OH-vitamin D, calcium, phosphorus, parathormone (PPTH), osteocalcin (OC), β-crosslaps, and bone alkaline phosphatase. For the evaluation of antioxidant systems, blood samples were collected at 08:00 AM, after overnight fast, immediately centrifuged and stored at –80 °C until assayed, to evaluate Total Antioxidant Capacity (TAC). Finally, bone mineral density was assessed by DEXA.

The following methods were used for hormone assay: Electro-ChemiLuminescent method (ECLIA) for PTH (n.r. 14–72 pg/ml), OC (n.r. 10–45 ng/ml), β-crosslaps (n.r. 0.2–0.7 ng/ml); ChemoLuminescent Immunoassay for TSH (n.r. 0.35–2.80 μUI/ml), FT3 (n.r. 2.4–4.2 ng/ml), FT4 (n.r. 8.5–16.5 pg/ml), IGF-1 (n.r. 80–330 ng/ml), FSH (2.5–11 μIU/ml), LH (2.5–10 μIU/ml), E2 (normal values < 44 ng/ml), DHEAS (n.r. 800–3500 ng/ml), T (n.r. 0.20–2.00 ng/ml), cortisol (n.r. 60–220 ng/ml), vitamin D (n.r. 31–100 ng/ml), bone alkaline phosphatase (n.r. 5.5–25 μg/l), and Chemiluminescent Microparticle ImmunoAssay (CMIA) for LH (2.5–15 nM/l). Calcium was measured with Arsenazo III method, phosphate with colorimetric assay.

As IGF-1 is concerned, we also calculated the median value, according to sex and age, using reference provided by Liason® Analyzer producer (DiaSorin, Vercelli, Italy), to classify patient with low or normal IGF-1.

Total Antioxidant Capacity (TAC) was evaluated, with a modification of the method developed by Rice-Evans and Miller [18], as previously described [19]. The method is based on the antioxidants inhibition of the absorbance of the radical cation ABTS+ formed by...
interaction between ABTS [2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt; 150 μM] and ferrylmyoglobin radical species, generated by activation of metamyoglobin (2.5 μM) with H2O2 (75 μM).

Aliquots of the frozen plasma were thawed at room temperature and 10 μl of the samples was tested immediately. The manual procedure was used with only minor modifications, that is, temperature at 37 °C to be in more physiological conditions and each sample assayed alone to carefully control timing and temperature. The reaction was started directly in cuvette through H2O2 addition after 1 min equilibration of all other reagents (temperature control by a thermocouple probe, model 1408 K thermocouple (Digitron Instrumentation Ltd, Scunthorpe, UK) and followed for 10 min under continuous stirring, monitoring at 734 nm, typical of the spectrscopically detectable ABTS∗+. The presence of chain-breaking antioxidants induces a lag time (the Lag phase) in the accumulation of ABTS∗+ whose duration is proportional to the concentration of this type of antioxidants. Antioxidant capacity afforded by chain-breaking antioxidants is expressed as length of Lag phase (LAG, sec). Trolox, a water-soluble tocopherol analogue, was used as a reference standard and assayed in all experiments to control the system. Absorbance was measured with an Agilent 8453 UV/Vis spectrophotometer (Palo Alto, CA, USA) equipped with a cuvette stirring apparatus and a constant temperature cell holder.

Measurements of pH were made with a PHM84 Research pH meter (Radiometer, Copenhagen, Denmark); the electrode response was corrected for temperature. Unless stated differently, experiments were repeated 2–3 times; qualitatively similar results were obtained.

Concerning oxidative parameters, group A presented higher levels of LAG than group B (Fig. 4). On the contrary, when dividing patient according to IGF-1 levels (separating patients IGF-1 levels over or under the median for each age), no differences in LAG values were observed.

Finally, interesting results were obtained with a further stratification in 3 groups of patients according to fT3 levels, separating group B in 2 subgroups according to median value of fT3 observed in this one (2.6 pg/ml). In fact, among 21 patients, 12 exhibited low-normal values (2.4–2.6 pg/ml) and 9 normal values. Mean OC level in these 3 subgroups are reported in (supplementary material). We found that also in low-normal fT3 patients OC levels were significantly lower than in normal fT3 patients.

Discussion

Our data confirm multi-hormonal derangement in FHA, with negative impact on bone metabolism, according to literature [3–9], adding some new information on their reciprocal influence and regulation on antioxidant systems.
In our cohort, a significant number of patients showed low fT3 levels. Data of BMD in our low-fT3 patients showed a worse picture in comparison to normal ones. Low fT3 syndrome, usually considered as an adaptive mechanism, therefore not to be treated by replacement therapy, as in other condition of systemic diseases [21], could be responsible for negative consequences in the bone, representing a negative worsening factor in synergy with low IGF-1 and high cortisol levels.

When dividing patients according to fT3 levels, we found significantly lower levels of OC, IGF-1, and significantly increased cortisol levels. On the contrary, estradiol levels did not differ between the 2 groups. Moreover, a significant correlation was present between fT3 and IGF-1. Both IGF-1 and fT3 significantly correlated with osteocalcin, accordingly to a positive action of both on osteoblastic activity.

A condition of GH resistance is present in patients affected by anorexia nervosa [22]. Even our patients showed low levels of IGF-1, significantly correlated with fT3 and osteocalcin. Although GH itself was not measured in our study, the mechanism involved in FHA is probably the same. Low IGF-1 levels are associated with an increased fracture risk both in men [23] and women [24]. Both GH, via direct action, and locally produced IGF-1 exert independent, but integrated effects on skeletal cytotypes; the cellular machinery is even more elaborate when considering the modulatory activity of IGF-binding proteins [25]. Moreover estrogens have profound interactions with such systems, also explaining sex-related differences in bone metabolism [26]. Recently, other mechanisms have been claimed to explain GH resistance in anorexia nervosa [27], such as increased FGF-21, low insulin and increased ghrelin, the increased expression of the deacetylase Sirtuin-1; all these factors underline the link between metabolic request and defense mechanisms. If such mechanisms operate also in other forms of FHA is not known. Anyhow, in our study IGF-1 levels correlated with

| Table 2 Mean ± SEM of hormonal parameters and bone metabolism parameters. |
|-----------------------------|-----------------------------|-----------------------------|
|                             | Group A                     | Group B                     | p               |
| fT3 (pg/ml)                 | 2.19 ± 0.04                 | 2.68 ± 0.06                 | <0.05           |
| fT4 (pg/ml)                 | 9.20 ± 0.24                 | 10.18 ± 0.27                | NS              |
| TSH (µUI/ml)                | 1.41 ± 0.14                 | 1.68 ± 0.22                 | NS              |
| FSH (µUI/ml)                | 5.22 ± 0.45                 | 5.70 ± 0.39                 | NS              |
| LH (µUI/ml)                 | 2.16 ± 0.43                 | 3.64 ± 0.64                 | NS              |
| E2 (pg/ml)                  | 25.05 ± 2.57                | 32 ± 3.97                   | NS              |
| DHEAS (ng/ml)               | 2513 ± 230.79               | 2416.53 ± 245.55            | NS              |
| T (ng/ml)                   | 0.44 ± 0.06                 | 0.42 ± 0.13                 | NS              |
| Cortisol (ng/ml)            | 163.86 ± 13.52              | 116.84 ± 7.51               | <0.05           |
| Vitamin D (ng/ml)           | 28.07 ± 2.49                | 28.84 ± 1.60                | NS              |
| Calcium (mg/dl)             | 9.66 ± 0.06                 | 9.71 ± 0.06                 | NS              |
| Phosphorus (mg/dl)          | 3.42 ± 0.11                 | 3.61 ± 0.09                 | NS              |
| PTH (pg/ml)                 | 35.65 ± 2.42                | 40.32 ± 3.50                | NS              |
| β-Cross-laps (ng/ml)        | 0.52 ± 0.04                 | 0.53 ± 0.04                 | NS              |
| Bone alkaline phosphatase (µg/l) | 10.85 ± 4.62               | 23.18 ± 7.37               | NS              |

NS: Not significant.
**Fig. 2** Mean ± SEM values of OC (left panel) and IGF-1 (right panel) in the 2 groups. *p < 0.05.

**Fig. 3** Correlations between OC and FT3 (left panel) and IGF-1 (right panel).

**Fig. 4** Mean ± SEM values of LAG in the 2 groups in accordance to FT3 values (left panel) and IGF-1 (right panel). *p < 0.05, LAG: Duration of latency phase before the appearance of radical species (see text for explanation).
osteocalcin, suggesting a promoting action on osteoblast production. IGF-1 and OC show parallel patterns in different models in literature [28, 29], however, studies about skeletal maturation suggest a triggering action on OC synthesis [30].

The effects of low FT3 are less clear. Osteoblasts have receptors for thyroid hormone [31]; experimental animals KO for thyroid receptors have a reduced trabecular BMD and high marrow fat [32], resembling alterations of hypoestrogenic women. Studies on FT3 actions on osteoblasts are contradictory [33], especially when considering that both hypo- and hyperthyroidism can induce osteoporosis; but they generally suggest positive FT3 effect on differentiation and activity of osteoblasts, while the actions on osteoclasts seem to be indirect. As differentiation and proliferation is concerned, induction of IGF-1, IGFBP-2, and -4, FGF receptors and signaling are stimulated by FT3 [34–36]. About osteoblast activity, FT3 has been demonstrated to stimulate type I collagen synthesis and post-translational modification, alkaline phosphatase expression, osteopontin and osteocalcin synthesis and secretion [37, 38]. These experimental data well fit with the direct correlation between FT3 and osteocalcin in our patients. The effect on osteoclasts, mediated by osteoprotegerin, are still controversial [33]. In the model of FHA, the problem could be related to local deiodination rather than low circulating FT3 levels; in such sense, studies performed in mice, with deletion of type 2 deiodinases gene (dio2) suggest the key role of FT3 in osteoblast activity [39].

Cortisol levels, increased in group A could also have a relevant role in our findings, directly contributing to reduced bone mineral density, but also influencing the conversion of l-thyroxine to FT3 [40]. Both increased cortisol and low FT3 could express a worse hypothalamic derangement and metabolic condition of this group. Whatever the mechanism, cortisol levels were not themselves correlated significantly neither to OC, nor to FT3 and LAG.

A great importance in negative skeletal condition is usually attributed to the state of hypoestrogenism [22], since estrogens exert a triple action, activating bone remodeling units, suppressing bone reabsorption and stimulating bone formation [12]. Osteoclastic activity is inhibited by different mechanisms [41], including inhibition of RANKL production and increased osteoprotegerin gene expression [42]. Other cytokines, favoring bone reabsorption, such as macrophage-colony stimulating factor (M-CSF), interleukins 1 and 6, tumor necrosis factor α (TNF-α), are inhibited by estrogens. They indirectly help osteoblastic activity, decreasing sclerostin (which inhibits osteoblastic WNT signaling) [43] and preadipocyte factor-1 (Pref-1), member of EGF family, which inhibits the differentiation of osteoblasts from mesenchimal progenitor cells [44]. Finally, estrogens stimulate other effectors, such as bone morphogenetic protein 6-BMP6 and transforming growth factor β; but also IGF-1, locally produced in the bone after GH stimulation, is augmented by estrogens. They also increase the expression of vitamin D receptors [45]. Such complex and pleomorphic action can obviously have an impact on skeleton and some studies suggest a minimal threshold of 40–50 pg/ml to observe effects on bone [46]. However, we did not find differences in estradiol in our 2 groups, emphasizing additional influences of other systems.

Even if low FT3 and IGF-1 could have a synergic effect on bone, our data suggest that they could work with different mechanisms, in fact only FT3 seemed to influence antioxidant systems in our population. Greater LAG values in low-fT3 patients suggest a greater oxidative stress in such group with a compensatory increase in anti-oxidant systems. Previously we have shown that thyroid hormones profoundly affect the antioxidant defense of the body, leading to a condition of oxidative stress [16]. Both hyper- and hypothyroidism can induce oxidative stress; but in the case of hypothyroidism, the low FT3 condition could worsen the oxidative status of the cell, with a vicious circle. Mechanism of competition on glutathione, which is a cofactor of deiodinases, but also strong antioxidant, have been claimed. Also growth hormone deficiency/ resistance is associated with oxidative stress, even if with a different pattern of antioxidants [47]. While in this study we did not find differences in TAC in relation to IGF-1, the values of LAG were significantly different in groups with low or normal FT3. The augmented LAG could express a compensatory mechanism to a greater oxidative stress, directly influencing bone metabolism, as shown in other in vivo models [48].

Under this profile, it could be of interest that also patients with low-normal FT3 have low osteocalcin level, suggesting that the biochemical mechanisms operating at cellular levels can be very precocious, requiring therefore a special attention.

In conclusion, osteopenia/osteoporosis in FHA should be considered a multifactorial problem. While no doubts exist that low estrogens and vitamin D deficiency can play a pivotal role, other hormonal derangement, such as low FT3 and IGF-1, although by different mechanisms, could be considered in such condition.

Nevertheless, there are two main potential restrictions to consider in the present study. First, the number of subjects in both groups is slightly small, so its statistical power is limited, thus our findings will need to be confirmed in a larger population. Second, this cohort-study and the power analysis cannot draw a cause-effect conclusion about oxidative stress and osteoporosis in patients affected by FHA.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


[33] Williams GR. Thyroid hormone actions in cartilage and bone. Eur Thyroid J 2012; 3–13

[34] Xing W, Govoni KE, Donahue LR et al. Genetic evidence that thyroid hormone is indispensable for prepubertal insulin-like growth factor-I expression and bone acquisition in mice. J Bone Miner Res 2012; 27: 1067–1079


[36] Stevens DA, Harvey CB, Scott Aj et al. Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol Endocrinol 2003; 17: 1751–1766


[38] Gouveia CH, Schultz JJ, Bianco AC et al. Thyroid hormone stimulation of osteocalcin gene expression in ROS 17/2.8 cells is mediated by transcriptional and post-transcriptional mechanisms. J Endocrinol 2001; 170: 667–675


